SHILPAMED Shilpa Medicare Q4 FY26 results (Jan–Mar 2026) and concall
Shilpa Medicare delivered strong Q4 and full-year FY26 results, achieving record revenues and significant EBITDA margin expansion driven by operating leverage. The company is actively diversifying its portfolio across APIs, formulations, biologics, and ADCs, with a robust pipeline of new products and strategic investments in CDMO capabilities. While US formulation revenue faced headwinds from product discontinuation, the focus has shifted to specialty products and global market expansion, with several key launches and regulatory milestones expected in FY27 and FY28.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 59.5%, net profit up 1283.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 130 | 125 | 126 | 92 | 135 +4% | 166 +33% | 201 +60% |
| EBITDA | 43 | 22 | 38 | 17 | 39 −9% | 31 +41% | 60 +58% |
| Net profit | 30 | 16 | -6 | 21 | 31 +3% | 16 +0% | 71 +1283% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
